Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma.
Han X, Zhang M, Wang H, Zhang Q, Li W, Hao M, Gao Y, Jin J, Ren H, Tang Y, Hong X, Ke X, Su H, Gui L, Luo J, Xie L, Gai W, Shi Y. Han X, et al. Among authors: ke x. Chin J Cancer Res. 2022 Dec 30;34(6):601-611. doi: 10.21147/j.issn.1000-9604.2022.06.08. Chin J Cancer Res. 2022. PMID: 36714342 Free PMC article.
[Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
Shi YK, He XH, Yang S, Wang HQ, Jiang ZF, Zhu YZ, Ke XY, Zhang Y, Liu YP, Zhang WJ, Wang Z, Shi QZ, Xie XD, Zhang HL, Wang JJ, Luo DY, Zheng QS, Sun RY. Shi YK, et al. Zhonghua Yi Xue Za Zhi. 2006 Dec 26;86(48):3414-9. Zhonghua Yi Xue Za Zhi. 2006. PMID: 17313855 Clinical Trial. Chinese.
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators. Coiffier B, et al. Lancet Oncol. 2011 Aug;12(8):773-84. doi: 10.1016/S1470-2045(11)70150-4. Epub 2011 Jul 1. Lancet Oncol. 2011. PMID: 21724462 Clinical Trial.
Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China.
Gong D, Li W, Hu LD, Shen JL, Fang MY, Yang QM, Wang HX, Ke XY, Chen HR, Wang Z, Liu H, Liu F, Ma YG, Wang JW, Li HH, Wang QS, Jing Y, Gao XN, Dou LP, Li YH, Luo JM, Yu L. Gong D, et al. Acta Haematol. 2016;136(4):201-209. doi: 10.1159/000448209. Epub 2016 Sep 17. Acta Haematol. 2016. PMID: 27640088
Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study.
Leng Y, Hou J, Jin J, Zhang M, Ke X, Jiang B, Pan L, Yang L, Zhou F, Wang J, Wang Z, Liu L, Li W, Shen Z, Qiu L, Chang N, Li J, Liu J, Pang H, Meng H, Wei P, Jiang H, Liu Y, Zheng X, Yang S, Chen W. Leng Y, et al. Among authors: ke x. Cancer Chemother Pharmacol. 2017 Jun;79(6):1141-1149. doi: 10.1007/s00280-017-3310-0. Epub 2017 May 12. Cancer Chemother Pharmacol. 2017. PMID: 28500554 Clinical Trial.
2,284 results